Stock Information
Hemab Therapeutics Holdings Inc (COAG)
Ticker Symbol: COAG
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $1,845.33 mil
Piotroski score: 2
PE Ratio: N/A
EPS (TTM): N/A
Revenue (TTM): $0.00 M
Dividend Yield: N/A%
ROE: N/A%
Latest News
-
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
Wed, Jul 15, 2026 3:52 AM
-
Hemab Therapeutics Presents Clinical, Preclinical Data From Sutacimig In Glanzmann Thrombasthenia And Factor VII Deficiency At International Society On Thrombosis And Haemostasis 2026 Congress
Tue, Jul 14, 2026 7:49 AM
-
Mega-Deals Push H1 2026 U.S. Equity Issuance Into Orbit
Tue, Jul 14, 2026 3:55 AM
-
Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47
Mon, Jul 13, 2026 2:39 PM
-
Hemab Advances Bleeding Disorder Pipeline
Mon, Jul 13, 2026 1:47 PM
-
CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55
Mon, Jul 13, 2026 9:32 AM
-
Wedbush Reiterates Outperform on Hemab Therapeutics Hldgs, Maintains $55 Price Target
Mon, Jul 13, 2026 9:14 AM
-
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $52
Mon, Jul 13, 2026 6:05 AM
-
Reported Sunday, Hemab Therapeutics Presents New HMB-002 Clinical Data Showing ≥2.4-Fold Dose-Dependent VWF And FVIII Increases In Von Willebrand Disease, Introduces HMB-003 For Heavy Menstrual Bleeding At ISTH 2026 Congress
Mon, Jul 13, 2026 2:10 AM
Key Financials
Financial data not available
